LA JOLLA, CA—La Jolla Institute for Immunology (LJI) is pleased to welcome Emily Holmes, Ph.D., J.D., to the Institute’s Board of Directors. Holmes has more than 30 years of experience in the areas of patent law, ethics, and research compliance. She brings with her in-depth knowledge of clinical trials and the challenges of taking research from bench to bedside.
“Emily Holmes has a deep understanding of the challenges and opportunities in biomedical research,” says LJI President and CEO Erica Ollmann Saphire, Ph.D. “As a member of our Board, Dr. Holmes’s expertise is critical as LJI expands its research and collaborations around the world.”
Holmes currently serves as Senior Director of Research Compliance and Regulatory Affairs at Seattle Children’s. Under her leadership, researchers and physicians with Seattle Children’s conduct potentially life-saving research with the support, education, and oversight to stay in research compliance.
Prior to her role at Seattle Children’s’ Holmes led compliance efforts at Scripps Research in La Jolla, CA, one of the largest biomedical research institutes in the world. From 1991 to 2019, Holmes served in various positions, including serving as a patent attorney and drafting patents on behalf of the Institute. She went on to supervise the Scripps Research research cores and specialize in research compliance. By the time she moved on, Holmes had achieved the role of Vice President of the Scripps Research Office of Policy, Education and Risk Administration.
In addition to her research and administration skills, Holmes has spearheaded the drafting of regulatory policy. She is registered with the US Patent and Trademark Office and is a current member of the California Bar. She is certified in healthcare research compliance (CHRC).
“Serving as a LJI board member provides a unique opportunity for me to contribute in a governance leadership role to guiding LJI’s vision, strategic planning, regulatory compliance, and sustainability in its global health initiatives,” says Holmes.
Holmes is enthusiastic supporter of LJI research initiatives to better understand sex-based differences in the immune system—and the individual variation that controls responses to infectious disease. “Given the continuing evolution of the SARS-CoV-2 virus, LJI is in a key position as a partner in understanding and mitigating this global health pandemic,” says Holmes.
###
